EUCTR2009-011990-34-AT进行中（未招募）不适用
Cytokines and Inflammatory Marker during Therapy in Major Depression with Celecoxib - CITICOX
Klinik für Psychiatrie und Psychotherapie der Ludwig Maximilian Universität München0 个研究点目标入组 128 人开始时间: 2012年7月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 128
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Major depression diagnosed by psychiatrist
- •2) DSM IV TR: 296.2x single depressive episode or 296.3x recurrent depressive episode
- •3) HamD-17 score = 22
- •4) Informed consent
- •5) Age between 18 and 60 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Psychotic depression or bipolar disorder, drug or alcohol addiction, schizoaffective disorders, schizophrenia. Other disorders (e.g. obsessive compulsive disorder, anxiety disorder, personality disorder) in case the symptoms predominate the clinical picture.
- •2) Unsuccessful treatment with more than 2 antidepressant medications (at therapeutically adequate doses and duration) during current episode.
- •3) Concomitant use of psychotropic drugs, including mood stabilizers, besides defined co-medication.
- •4) Immediate risk for suicidal behavior (3 on HamD-17 rating scale or 5 on MAD Rating Scale).
- •5) Women who are pregnant, breast feeding or planning to become pregnant during the course of study.
- •6) Women who are not post-menopausal (no natural menopause established in retrospect after 12 consecutive months of amenorrhea without hormone replacement therapy during the last 5 months), surgically sterilized or using a highly effective method of contraception (an implanted or injected hormonal contraceptive, some intrauterine contraceptive devices (IUDs) containing hormones, sexual abstinence, or have a vasectomized partner). Females using combined oral contraceptives should use a different or additional highly effective method of contraception as listed above.
- •7) Any history of cardiovascular disease (e.g. angina, heart attack, stroke, congestive heart failure), uncontrolled high blood pressure, documented peripheral arterial insufficiency and symptomatic, clinically significant claudication, a history of peripheral arterial embolism or cerebrovascular disease.
- •8) Patients at risk of QT/QTc interval prolongation (QTc> 450 ms, family history of long QT syndrome or use of medication prolonging QT/QTc interval).
- •9) History of coronary heart disease (CHD) or any other heart disease.
- •10) Serum NTproBNP = 125 pg/mL indicating (sub-) clinical heart failure.
- •11) History of upper or lower gastrointestinal (GI) ulceration, perforation and/or obstruction.
- •12) History of upper or lower GI bleeding within the previous year.
- •13) History of inflammatory bowel disease.
- •14) Undergoing cancer chemotherapy.
- •15) Known HIV infection or clinically manifest Acquired Immune Deficiency Syndrome (AIDS), diabetes, asthma, COPD, Parkinson’s or Alzheimer’s disease, or any other serious condition likely to interfere with the conduct of the trial.
- •16) Clinically relevant hepatic or renal impairment (serum albumin < 25 g/L or Child-Pugh > 10 or renal GFR < 30 mL/min), or other clinically significant physical findings or clinically significant laboratory results at screening or baseline, as determined by the investigator.
- •17) History of allergy to sertraline, celecoxib, sulfonamides or closely related compounds, or excipients.
- •18) History of hypersensitivity or intolerance to pain medications.
- •19) Use of pain medication, such as a COX-2 inhibitor, NSAID (non-steroidal anti-inflammatory drug, including aspirin) or acetaminophen (syn. paracetamol) within 72 hours prior to study entry (24 hours for short-acting drugs such as aspirin or acetaminophen).
- •20) Patients currently taking warfarin.
- •21) Participation in a study of an investigational drug or device concomitantly or within 30 days prior to this study.
- •22) Patients thought to be unreliable or incapable of complying with the requirements of the protocol.
- •23) Treatment with monoamino oxidase inhibitors during the last 14 days or treatment with fluoxetine during the last 6 weeks.
研究者
相似试验
进行中（未招募）
1 期
Cytokines and Inflammatory Marker during Therapy in Major Depression with Celecoxib - CITICOXEUCTR2009-011990-34-DEClinic for Psychiatry and Psychotherapy of the Ludwig Maximilian University57
进行中（未招募）
不适用
Evaluation of the expression of inflammatory cytokines in the gingival crevicular fluid of patients with Covid-19.inflammationC01.748.214RBR-4473k7yniversidade Estadual do Oeste do Paraná
尚未招募
不适用
Investigating potential biomarkers in Myalgic Encephalomyelitis Chronic Fatigue Syndrome (MECFS) patientsACTRN12620001150932South Australian Health & Medical Research Institute60
已完成
不适用
Clinical value of the cytokine levels in the postoperative drainage fluid for outcome in patients with colorectal diseases after open surgery and laparoscopic surgeryColorectal cancerJPRN-UMIN000030434Department of surgery, National Defense Medical College500
进行中（未招募）
1 期
Evaluation of inflammatory markers in patients undergoing a short-term aerobic exercise program while hospitalized due to acute exacerbation of COPDChronic obstructive pulmonary disease with acute lower respiratory infectionJ44.0RBR-7yv765Faculdade de Medicina de Botucatu /UNESP